H.R. 1051: To amend the Federal Food, Drug, and Cosmetic Act to allow for the approval of an abbreviated new drug application submitted by a subsequent applicant in the case of a failure by a first applicant to commence commercial marketing within a certain period, and for other purposes.

H.R. 1051 is a federal bill in the 119th Congress. Currently, the first company to get FDA approval for a generic drug receives 180 days of exclusive marketing rights, which typically begins when they start selling the drug. This bill changes that by allowing the FDA to approve a second generic drug… See its sponsors, how members voted, and a plain-English breakdown on PolityLens.